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Abstract
Introduction: Latent autoimmune diabetes in adults (LADA) is a slow-developing form of autoimmune diabetes, characterised by the 
presence of type 1 diabetes-associated autoantibody and presentation at diagnosis similar to patients with type 2 diabetes. The aim of 
this study was to determine the prevalence of auto-antibodies related to endocrine autoimmune diseases in patients with LADA and to 
assess their association with HLA genotype. 
Material and methods: We evaluated the presence of anti-thyroglobulin (ATG), anti-thyroid peroxidase (ATPO), anti-tissue transglu-
taminase IgA (ATTA), and anti 21 hydroxylase (A21H) in 70 patients with LADA, 69 with Type 2 diabetes, and in 50 healthy controls HLA 
genotype was assed in subpopulation of sluclied subjects.
Results: The presence of ATPO (28.6 vs. 10%); ATG (28.6 vs. 14%) was higher in patients with LADA in comparison to healthy controls 
and ATPO in comparison to patients with type 2 diabetes (38.6 vs. 17.4 %). In patients with LADA the presence of autoimmune thyroid 
autoantibodies was associated with newly diagnosed subclinical hypothyroidism; almost 7% of patients presented with high TSH. The 
presence of A21H (2.86 vs. 5.8 vs. 6.1%) and ATTA (2.86 vs. 4.3 vs. 6.0%) was not different between groups. Patients with high TSH level 
were positive for DQA1*0301 and DRB1*04 HLA genotype: DQB1*0201 and DQB1*02 were higher in patients positive for ATTA.
Conclusions: Patients with LADA have higher prevalence of thyroid autoimmune diseases. 
In patients with LADA similarly to type 1 genotype DQA1*0301 seems to CONFER susceptibility to thyroid autoimmunity, and DQB1*0201 
to celiac disease. (Endokrynol Pol 2016; 67 (2): 197–201)
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Streszczenie 
Wstęp: Późno ujawniająca się cukrzyca autoimmunologiczną u osób dorosłych cechuje się obecnością przeciwciał skierowanych przeciwko 
antygenom wysp trzustkowych u pacjentów z kliniczną prezentacją cukrzycy typu 2. Celem pracy była ocena występowania chorób 
autoimmunologicznych u pacjentów z cukrzycą LADA oraz ocena związku z genotypem HLA. 
Materiał i metody: W obecnej pracy oceniono występowanie przeciwciał przeciwko-tyreoglobulinie (ATG), przeciwko peroksydazie 
tarczycowej (ATPO), przeciwko transglutaminazie tkankowej IgA (ATTA) oraz przeciwko 21 hydroksylazie (A21H) u 70 pacjentów 
z cukrzycą LADA, 69 z cukrzycą typu 2 oraz 50 osób z grupy kontrolnej oraz genotyp HLA. 
Wyniki: Częstość występowania przeciwciał ATPO (28,6 vs. 10%), ATG (28,6 vs. 14%) była wyższa w grupie pacjentów z cukrzycą typu 
LADA w porównaniu do grupy kontrolnej oraz ATPO (38,6 vs. 17,4%) w porównaniu z pacjentami z cukrzycą typu 2. W grupie pacjen-
tów z cukrzycą typu LADA istotnie cześciej stwierdzono obecność przeciwciał ATPO oraz ATG, którym towarzyszyly nowowykryte 
zaburzenia kliniczne funkcji tarczycy. Częstość występowania przeciwciał przeciwko 21 OH hydroksylazie (2,86 vs. 5,8 vs. 6,1%) oraz 
przeciwko transglutaminazie w klasie IgA (2,86 vs. 4,3 vs. 6,0%) nie różniła się pomiędzy badanymi grupami. Genotyp HLA DQA1*0301 
występował częściej u pacjentów z autoimmunologiczną niedoczynnością tarczycy, nastomiast DQB1*0201 u pacjentów z przeciwciałami 
ATTA będącymi markerem choroby trzewnej. 
Wnioski: U pacjentów z cukrzycą LADA częściej występują przeciwciała skierowane przeciwko antygenom tarczycy współistniejące 
z subliniczną niedoczynością tarczycy. (Endokrynol Pol 2016; 67 (2): 197–201)
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Introduction
Latent autoimmune diabetes in adults (LADA) is 
a slowly progressing form of autoimmune diabetes, char-
acterised by the presence of type 1 diabetes-associated 
autoantibody and presentation at diagnosis without 
acute clinical symptoms of insulin deficiency [1–3]. 
Similarly to Type 1 diabetes, patients with LADA 
have also a higher risk for endocrine autoimmune dis-
eases. Patients with LADA have higher risk for thyroid 
and adrenal autoimmunity [4–7] and for celiac disease 
[6, 8, 9]. The presence of organ-specific autoantibodies 
is also higher in people with LADA and HLA-DR3-DQ2 
antigens [5]. 
The aim of this study was therefore to determine 
the presence of antibodies associated with endocrine 
autoimmunity other than type 1 diabetes and asses its 
association with HLA genotype in patients with LADA. 
Material and methods
The study protocol was approved by the Ethics Com-
mittee of the Medical University of Białystok. Informed 
consent was obtained from all patients and controls to 
be included in the study. 
Diabetes was diagnosed according to the World 
Health Organisation (WHO) 1999 criteria. Terms and 
Classifications: those for whom insulin treatment was 
started within three months from diagnosis were clas-
sified as having type 1 diabetes. Diagnosis of LADA was 
made according to criteria proposed by Immunology 
Diabetes Society and Action LADA [1]. Those who were 
aged ≥ 30 years at diagnosis, were autoantibody posi-
tive, and insulin independent for a minimum of the first 
three months from diagnosis were considered to have 
LADA. Participants who were GADA- (glutamic acid 
decarboxylase antibody), IAA- (Anti Insulin Antibody), 
or IA2 (Insulinoma-associated antibody)-negative and 
insulin independent were considered to have type 
2 diabetes. The current study consists of 70 patients 
with LADA, 69 with type 2 diabetes, and 50 healthy 
controls. The majority of patients were newly diagnosed 
with short duration of diabetes and did not have any 
known endocrine autoimmune disorders diagnosed 
before enrolment.
Laboratory measurements
Laboratory measurements were performed as previ-
ously described (10). TSH: thyroid stimulatory hormone 
(0.47–4.5 microIU/mL), anti-thyroglobulin antibodies 
ATG (IU/L), and anti-thyroid peroxidase antibodies 
ATPO (IU/L) were measured by microparticle enzyme 
immunoassay (MEIA) [11]. Anti 21 hydroxylase anti-
bodies (A21H) were measured with RIA and anti tissue 
transglutaminase IgA (ATTA) antibodies with ELISA 
(cutoff higher than 20 reference units per ml). Any ATG 
positive antibody higher than two standard deviations 
from the mean in the whole studied population were 
consider as positive (cutoff 237 IU/L), similarly for ATPO 
(cutoff 49.5 IU/L) and A21H (cutoff 0.74 IU/L). 
HLA genotype was performed as previously 
described [12]. 
Statistical methods
Differences in antibody frequencies were tested by the 
c2 test. Numerical data were expressed as mean and 
standard deviation unless indicated otherwise. Statis-
tical significance was assessed by the Wilcoxon-Mann-
Whitney test. To calculate the probability of the presence 
of positive ATPO and ATG by sex the Cochran-Armitage 
Trend Test was used. 
A probability value of less than 0.05 was considered 
statistically significant. Analyses were carried out with 




Patients with LADA when compared to GADA-, IAA-, 
and IA2-negative diabetes were more likely to be 
younger, younger at the time of diagnosis, and had 
lower BMI and fasting C peptide levels. Patients with 
LADA when compared to healthy controls were more 
likely to be female and had lower fasting C peptide. 
Characteristics of patients with LADA, patients with 
GADA-, IAA-, and IA2-negative diabetes and healthy 
controls are depicted in Table I. 
The presence of endocrine auto-antibodies
Mean plasma concentration for ATG, ATPO, and A21H 
were higher in LADA than in GADA, IAA-, and IA2-
negative diabetes. Mean ATPO and A21H were also 
higher in LADA than in healthy controls (Table II).
Presence of ATPO (28.6 vs. 10 %); ATG (28.6 vs. 14%) 
was higher in patients with LADA in comparison to 
healthy controls and ATPO in comparison to GADA, 
IAA-, and IA2-negative diabetes (38.6 vs. 17.4 %) 
(Table II). Moreover, there was positive trend for ATG 
to be present more frequently among men and ATPO 
among women with LADA compared to both other 
groups (Table II). In patients with LADA the presence 
of thyroid autoimmune auto-antibodies was associ-
ated with newly diagnosed subclinical hypothyroid-
ism; over 7% of patients with LADA had high TSH 
levels. The presence of A21H (2.86 vs. 5.8 vs. 6.1%) and 
ATTA (2.86 vs. 4.3 vs. 6.0%) was not different between 
groups (Table II). 
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Autoimmune antibodies in relation  
to HLA genotype
As expected, DQB1*0201 and DQB1*02 genotypes were 
higher in patients with antibodies positive for celiac 
disease (ATTA positive). Patients positive for Addison 
disease (A21H positive) had lower DQB1*0301/4 and 
DQA1*0501. Patients with high TSH levels were posi-
tive for DQA1*0301 and DRB1*04 (Table III). 
Discussion
Latent autoimmune diabetes in adults (LADA), the 
slowly progressive form of autoimmune diabetes, is 
not a clear-cut disease but includes a population of 
patients with clinical presentation similar to type 2 
diabetes but with autoimmune markers typical for type 
1 diabetes [10]. In patients with LADA a higher rate of 
thyroid autoimmunity was extensively described [4–7] 
but not with association to HLA genotype. In our study 
patients with LADA also presented with higher rates 
for autoimmune thyroid disease markers, especially 
ATPO. Our results confirm the observations by Kucera 
et al. [6] that LADA had higher rate for ATPO, but not 
ATG in comparison to patients with type 2 diabetes. In 
agreement with a previous study, we found a higher 
prevalence of TPO antibodies in female LADA patients 
Table I. Baseline clinical characteristics in patients with LADA, GADA-, IAA-, and IA2-negative diabetes and healthy controls. 
Mean ± SD
Tabela I. Charakterystyka kliniczna pacjentów z LADA, pacjentów z cukrzycą typu 2 bez obecności przeciwciał (GADA, IAA, 
IA2) oraz  w grupie kontrolnej
LADA GADA, IAA-, and IA2-negative 
diabetes
Controls LADA vs. GADA, IAA-, and 
IA2-negative diabetes
LADA vs. Controls
Number 70 69 50
Age (years) 44 ± 13 49 ± 10 40 ± 6.9 0.008 0.252
Age at diagnosis (years) 40 ± 12 48 ± 11.5 < 0.001
BMI [kg/m2] 25.9 ± 4.5 29.5 ± 4.9 25.7 ± 3.1 < 0.0001 0.503
Sex F/M 41/29 38/31 20/30 0.677 0.044
Fasting C peptide [ng/mL] 0.67 ± 0.85 1.08 ± 1.27 1.68 ± 0.95 0.005 0.0001
BMI — body mass index; LADA — latent autoimmune diabetes in adults; GADA — glutamic acid decarboxylase antibody; IAA — anti insulin antibody;  
IA2 — insulinoma-associated antibody.
Table II. Presence of endocrine autoantibodies in patients with LADA, GADA-, IAA-, and IA2-negative diabetes and healthy 
controls
Tabela II. Obecność przeciwciał charakteryzujących autoimmunologiczne choroby endokrynologiczne u pacjentów z  LADA, 
pacjentów z cukrzycą typu 2 bez obecności przeciwciał (GADA, IAA, IA2) oraz w grupie kontrolnej
LADA GADA, IAA-, and IA2-
negative diabetes
Controls LADA vs. GADA, IAA-, and 
IA2-negative diabetes
LADA vs. Controls
Mean ± SD ATG IU/L 225 ± 163 212 ± 145 144 ± 115 0.001 0.712
Mean ± SD ATPO IU/L 127 ± 217 38 ± 57 39 ± 104 < .0001 < 0.001
Mean ± SD ATTA IU/mL 8.34 ± 42.9 5.21 ± 7.93 5.31 ± 12 0.610 0.135
Mean ± SD A21H IU/L 0.29 ± 0.17 0.35 ± 0.23 0.26 ± 0.24 0.049 0.075
TSH > 4.5 microIU/mL 5/70 (7.14%) 1/69 (1.45%) 1/50 (2%) 0.099 0.202
ATG positive 20/50 (28.6%) 19/50 (27.54%) 7/43 (14%) 0.892 0.059
Female 9/32(12.9%) 12/26 (17.4%) 5/15(10%) 0.655*
Male 11/18 (15.7%) 7/24 (10.1%) 2/28 (4%) 0.004*
ATPO positive 27/43 (38.6%) 12/57 (17.4%) 5/45 (10%) 0.005 < 0.001
Female 20/21 (28.57%) 7/31 (10.14%) 3/17 (6%) 0.002*
Male 7/22 (10.00%) 5/26 (7.25%) 2/28 (4%) 0.074*
ATTA positive 2/68 (2.86%) 3/66 (4.3%) 3/47 (6%) 0.637 0.396
A21H positive 2/68 (2.86%) 4/65 (5.8%) 3/46 (6.1%) 0.394 0.382
*the Cochran-Armitage Trend Test; LADA — latent autoimmune diabetes in adults; GADA — glutamic acid decarboxylase antibody; IAA — anti insulin antibody;  
IA2 — insulinoma-associated antibody; TSH — thyroid stimulatory hormone; ATG — anti-thyroglobulin antibody; ATPO — anti-thyroid peroxidase antibody;  
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[4]. Interestingly, in our study ATG was present more 
often among male LADA patients. 
Additionally, in our study autoimmune thyroid 
antibodies were associated with high TSH; this may 
suggest the presence of subclinical hypothyroidism. 
More recently, Jin et al. [13] reported that a high titre 
of GADA was a strong predictor for the development 
of thyroid autoimmunity in Chinese patients with type 
1 diabetes mellitus and LADA. In our analysis patients 
with TSH above the reference range presented with 
DQA1*0301 and DRB1*04, confirming their importance 
in susceptibility to thyroid autoimmunity [14, 15]. It is 
interesting to speculate that, additionally, viral infec-
tions could be playing a role in the development of 
thyroid autoimmune diseases and type 1 diabetes [16]. 
It is very well-established that patients with type 1 
diabetes are predisposed to the presence of other endo-
crine autoimmune diseases, including thyroid disease. 
In the Polish type 1 diabetes population the presence of 
ATPO and ATG was describe as being as high as 16% 
[17]. Currently the Polish Endocrinology Society recom-
mends active screening for thyroid disease in children 
with type 1 diabetes [18]. 
In patients with type 1 diabetes and LADA autoim-
mune markers for celiac disease are also present [6, 8, 9]. 
The presence of celiac disease confirmed by biopsy was 
estimated for about 10% in patients with type 1 diabetes 
in the Polish population [19]. Our analysis, contrary to 
previous observations, did not show a higher rate of 
celiac disease in patients with LADA [6, 8] and was in 
accordance with observations by Sanchez et al. [20]. 
Our study additionally confirms an association 
of the HLA genotype with autoimmune diseases. As 
expected, DQB1*0201 and DQB1*02 genotypes were 
higher in patients with antibodies positive for celiac 
disease and DQA1*0301, and DRB1*04 in patients with 
high TSH level. Similarly to previous studies, genotype 
DQA1*0301 seems to suggest susceptibility to thyroid 
autoimmunity, and DQB1*201 to celiac disease [14].
Conclusions
Patients with LADA have a higher prevalence of thyroid 
autoimmune markers. Screening for autoimmune thy-
roid diseases in patients with LADA similarly to type 1 
diabetes can be proposed. 
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